Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
After enrolling in the Moderna phase III clinical trial, I collected my own biological samples pre- and post-immunization in the event of being a recipient of the experimental vaccine. The evidence strongly supports the conclusion that I did not receive the placebo. The analysis is admittedly limited to an n of 1, but the results fit well with data taken from published works and represent one of the more comprehensive longitudinal evaluations of vaccine-elicited immunity within a single individual yet to be undertaken. Though the data amount to a well-documented anecdote, given its granularity, it is not without its insights and may be of further use in directing future longitudinal studies that have actual statistical significance.
‘Affinity escape’: Novel SARS-CoV-2 variants may escape immunity by raising the RBD-ACE2 affinity high enough to outcompete the avidity of neutralizing antibodies.
